features: Skin Cancer
FDA grants priority review for fixed-dose relatlimab plus nivolumab in melanoma based on RELATIVITY-047
The U.S Food and Drug Administration (FDA) has granted priority review for the fixed-dose combination of relatlimab, a LAG-3 targeting…
Top picks from ASCO 2021
VJOncology presents highlights from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!